These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25324884)

  • 21. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease.
    Jang W; Park J; Shin KJ; Kim JS; Kim JS; Youn J; Cho JW; Oh E; Ahn JY; Oh KW; Kim HT
    J Neurol Sci; 2014 Feb; 337(1-2):47-54. PubMed ID: 24289887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study.
    Cho SH; Lim HS; Ghim JL; Choe S; Kim UJ; Jung JA; Bae KS
    Clin Ther; 2009 May; 31(5):1046-53. PubMed ID: 19539105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD005225. PubMed ID: 23235621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
    Rudnicki SA; Berry JD; Ingersoll E; Archibald D; Cudkowicz ME; Kerr DA; Dong Y
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Jan; 14(1):44-51. PubMed ID: 22985432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurochemical correlates of functional decline in amyotrophic lateral sclerosis.
    Cheong I; Deelchand DK; Eberly LE; Marjańska M; Manousakis G; Guliani G; Walk D; Öz G
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):294-301. PubMed ID: 30467209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation.
    Lo Coco D; Marchese S; La Bella V; Piccoli T; Lo Coco A
    Chest; 2007 Jul; 132(1):64-9. PubMed ID: 17475635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patients.
    Pinto S; Gromicho M; de Carvalho M
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):445-448. PubMed ID: 31032642
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
    Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
    Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients?
    Korzets A; Ori Y; Chagnac A; Weinstein T; Herman M; Zevin D; Malachi T; Gafter U
    Clin Nephrol; 2000 Jan; 53(1):48-54. PubMed ID: 10661482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis.
    Karam C; Barrett MJ; Imperato T; MacGowan DJ; Scelsa S
    J Clin Neurosci; 2013 Nov; 20(11):1550-3. PubMed ID: 23815870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
    Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
    Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study.
    Juntas-Morales R; Pageot N; Marin G; Dupuy AM; Alphandery S; Labar L; Esselin F; Picot MC; Camu W
    Front Neurol; 2020; 11():363. PubMed ID: 32547467
    [No Abstract]   [Full Text] [Related]  

  • 37. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.
    Murdock BJ; Zhou T; Kashlan SR; Little RJ; Goutman SA; Feldman EL
    JAMA Neurol; 2017 Dec; 74(12):1446-1454. PubMed ID: 28973548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.
    Ehrenreich H; Fischer B; Norra C; Schellenberger F; Stender N; Stiefel M; Sirén AL; Paulus W; Nave KA; Gold R; Bartels C
    Brain; 2007 Oct; 130(Pt 10):2577-88. PubMed ID: 17728357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.